EXECUTIVE ENGAGEMENTS
POOL
3737
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
673
Interactions with Platform & by Email
PARTICIPANTS
112
Unique # Participated
VALIDATIONS
32
Responses Validated*
COMPANIES
41
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
111
PAGES
182
EDITION
6
PRICE
USD 4950
CODE
MCP14355
*Engagement stats are ongoing and dynamic
Login to access data silos
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Rare Endocrine Disease Treatment estimated at US$8.9 Billion in the year 2020, is projected to reach a revised size of US$11.5 Billion by 2027, growing at a CAGR of 3.6% over the analysis period 2020-2027. Acromegaly, one of the segments analyzed in the report, is projected to record a 4.2% CAGR and reach US$4.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Central Diabetes Insipidus segment is readjusted to a revised 3.4% CAGR for the next 7-year period.
The Rare Endocrine Disease Treatment market in the U.S. is estimated at US$2.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 3.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.
In the global Ahumada-Del Castillo Syndrome segment, USA, Canada, Japan, China and Europe will drive the 4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$960.1 Million in the year 2020 will reach a projected size of US$1.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.
SELECT PLAYERS
Amgen, Inc.; Corcept Therapeutics, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Ipsen Group; Novartis AG; Novelion Therapeutics, Inc.; Novo Nordisk A/S; Pfizer, Inc.; Shire PLC; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» Administration (Injectables, Oral, Other Administrations) » Indication (Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism, Other Indications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Rare Endocrine Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Rare Endocrine Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Rare Endocrine Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Acromegaly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Acromegaly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Acromegaly by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Central Diabetes Insipidus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Central Diabetes Insipidus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Central Diabetes Insipidus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Ahumada-Del Castillo Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Ahumada-Del Castillo Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Ahumada-Del Castillo Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hypoparathyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hypoparathyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hypoparathyroidism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Rare Endocrine Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rare Endocrine Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rare Endocrine Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Rare Endocrine Disease Treatment by Administration - Injectables, Oral and Other Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Rare Endocrine Disease Treatment by Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Administrations for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 41 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com